Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.9310
-0.0287-2.99%
Volume:63.23K
Turnover:61.20K
Market Cap:52.56M
PE:-0.55
High:0.9976
Open:0.9700
Low:0.9131
Close:0.9597
Loading ...

Prelude Therapeutics to Participate in Citizens Life Sciences Conference in New York

Reuters
·
Yesterday

Prelude Announces Presentations at 2025 AACR Annual Meeting

GlobeNewswire
·
26 Apr

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

Zacks
·
11 Apr

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Apr

3 Promising Penny Stocks With Market Caps Up To $300M

Simply Wall St.
·
01 Apr

Prelude Therapeutics Founder Acquires 28% More Stock

Simply Wall St.
·
29 Mar

Prelude Therapeutics CEO Makes Bold Stock Purchase!

TIPRANKS
·
19 Mar

Prelude Therapeutics Reports 2024 Financial Results

TIPRANKS
·
11 Mar

Prelude Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Mar

Prelude Therapeutics FY Sales $7.000M Beat $2.000M Estimate

Benzinga
·
10 Mar

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

TIPRANKS
·
10 Mar

Prelude Therapeutics sees cash runway into 2Q26

TIPRANKS
·
10 Mar

BRIEF-Prelude Therapeutics FY Operating Expenses USD 146.714 Million

Reuters
·
10 Mar

Prelude Therapeutics FY Operating Expenses USD 146.714 Million

THOMSON REUTERS
·
10 Mar

Press Release: Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Dow Jones
·
10 Mar

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

GlobeNewswire
·
05 Mar

Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
11 Feb

BRIEF-Prelude Therapeutics Names Bryant Lim As Permanent CFO

Reuters
·
06 Feb

Prelude Therapeutics Appoints Bryant D. Lim as CFO

TIPRANKS
·
06 Feb

Prelude Therapeutics Inc - Appoints Bryant D. Lim as Permanent CFO

THOMSON REUTERS
·
06 Feb